The FDA has approved a label update for a biologic to include data on psoriasis with genital area involvement.
Monday, May 23, 2016
The open-label extension (OLE) study evaluated the long-term safety and efficacy of etanercept (Enbrel) for pediatric psoriasis.
Friday, May 20, 2016
The Corrona Psoriasis Registry will track the drug safety reporting for ixekizumab (Taltz), a new biologic medication by Eli Lilly and Company that was recently FDA approved for the treatment of moderate to severe plaque psoriasis.
Thursday, April 28, 2016
A recent research study, published in the Arteriosclerosis, Thrombosis, and Vascular Biology, set out to determine if psoriasis is associated with abdominal aortic aneurysm, a complex multifactorial disease associated with a high morbidity and mortality.
Wednesday, April 6, 2016
Positive top-line results for the first Phase 3 study investigating tofacitinib (Xeljanz, Pfizer Inc.) for the treatment of psoriatic arthritis (PsA), Oral Psoriatic Arthritis triaL (OPAL) Broaden were recently released. T